Biocytics

Join Dr. John Powderly II MD at the Advanced Therapies Think Tank - AT3 session hosted on June 4th as he discusses whether different novel business models could help expand access to C>s globally.

As more advanced therapies move closer to broader clinical adoption, it’s becoming increasingly important to think beyond the therapy itself and consider point of care manufacturing to deliver therapies effectively.

That includes questions around:
🏥 treatment infrastructure
⚙️ operational scalability
🌍 regional access
💰 and long-term sustainability

Innovative science alone is not enough if patients cannot realistically access these therapies at scale.

Looking forward to discussing this alongside:
👤 Host: Lee Buckler
👥 Guests: Boro Dropulić, Catriona Crombie

Register now to join the conversation, live: https://zoom.us/webinar/register/7017791091745/WN_0D_RVbwDQnq_hmqlZGyvQA

Last week at the North Carolina Biotechnology Center (NCBiotech ), Dr. John Powderly II MD served as a keynote speaker at the "Hope is Not a Workflow" symposium which focused on advancing manufacturing for cell and gene therapy. 🧪

The initiative brings together developers, manufacturers, clinicians, patients, and regulators with a shared goal: to accelerate the delivery of safe, scalable, and accessible therapies.

Since our founding in 2005, Carolina BioOncology Institute (CBOI) and BioCytics has focused on advancing personalized immune cell approaches at the point of care, with a focus on research and pre-clinical development of new delivery models.

In 2026, hope alone is not enough for patients with metastatic cancer. Progress requires tangible change across the biopharma ecosystem, including new clinical delivery systems, innovative business models, and regulatory pathways that support point-of-care manufacturing.

A key part of this vision is a broader shift from cells as a drug product to cells as a patient-centered medical service, enabling more accessible and iterative innovation. We are proud to contribute to this ongoing conversation as the future of cell and gene therapy continues to evolve.

🚀 Big news at BioCytics! We’re thrilled to welcome Dr. Koray Atalag and Dr. Colby Ford to our Informatics Advisory Board.

Their expertise in digital health, genomics, and cloud AI will help drive innovation in autologous cell therapy and precision oncology.

Please join us in giving them a warm welcome! 💙

The BioCytics Human Applications Laboratory is hosting a 10 week paid Summer 2026 Internship in Huntersville, North Carolina. 🧪

This full time internship includes direct mentorship from BioCytics scientists and completion of an independent research project aligned with our mission to advance cellular therapies and personalized medicine for cancer.

📅 June 1 – August 10, 2026 (flexible dates)
🔬 Focus: Oncology immunotherapy research supporting our product pipeline
🎓 Seeking Junior, Senior, or Masters level students with a background in immunology or related sciences
🧬 Bench research experience and familiarity with flow cytometry preferred

To apply, email your resume with the subject line BioCytics 2026 Summer Internship to [email protected]
Applications accepted through March 31.

In honor of the heart behind the research, here is a little science inspired appreciation from BioCytics and Carolina BioOncology Institute.

What we love about research is curiosity, collaboration, and the relentless pursuit of better answers. That is why innovation is built on people who care deeply about discovery.